| Bioactivity | NCX 470 is a second-generation nitric oxide (NO)-donating prostaglandin analogue. NCX 470 effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. NCX 470 can be used for the research of cular hypertension and glaucoma[1][2]. |
| In Vivo | NCX 470 shows a better intraocular pressure-lowering efficacy than that of equimolar doses of bimatoprost in well-established animal models of glaucoma and ocular hypertension[1].NCX 470 (0.14% 30 μL; instillation; once) reduces IOP in transient ocular hypertensive rabbits[2].NCX 470 (0.042% 30 μL; instillation; once) is more effective than equimolar bimatoprost in cynomolgus monkeys with laser-induced ocular hypertension (OHT-monkeys), and normotensive dogs (ONT-dogs) at 18 hours post dosing[2]. Animal Model: |
| Name | NCX 470 |
| CAS | 1194396-71-8 |
| Formula | C31H46N2O8 |
| Molar Mass | 574.71 |
| Appearance | Oil |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |
| Reference | [1]. Impagnatiello F, et al. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br J Pharmacol. 2019 Apr;176(8):1079-1089. [2]. Impagnatiello F, et al. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models. Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6558-64. |